Concern is growing among many university life scientists that the inevitably increasing reliance on commercial funding for research may be jeopardising traditional academic standards. Governments faced with burgeoning science budgets are increasingly wooing industrial funds to help maintain their researchers. In Britain, the government has made particular efforts to bring together public and private funds within the university sector. But some believe that it is now time to rethink the relationship. "The problems of industrial funding of research are seen as a public issue as the importance of life sciences increasingly impinges on ordinary life," says Gill Evans, public policy officer for Britain's Campaign for Academic Freedom and Standards (CAFAS). Many researchers believe that the issues now need to be addressed.
One of the key issues heightening concern is the publication of the draft human genome sequence and the inevitable commercial interest in exploiting its content. The Association of the British Pharmaceutical Industry has recently published a report: Evolution and Revolution: How genomics will change health care which flags up just how keen pharmaceutical companies are to exploit the new information and how crucial commercial funding will be. But academics are increasingly concerned that they may be the losers in the new relationship with industry. "It's often small things like the pressure to publish now rather than later, or not to pursue some slightly offbeat piece of research," says Evans.
A recent meeting organised by CAFAS, highlighted some of the key problems. Nancy Olivieri, a haematologist at the Toronto University's Hospital for Sick Children, told of how her research led to difficulties. With public funding, she had been researching oral methods of chelation of iron which otherwise can lead to a fatal build up in the blood of thalassemia patients.
The problems of industrial funding of research are seen as a public issue and the importance of life science increasingly impinging on ordinary life
With a promising compound, she published her initial results. Further public funding was then withheld as the work was considered to be of commercial potential. But when she won commercial funding but found the compound failing to live up to its early promise, she fell into considerable difficulty with the company and her university.
She is particularly concerned about the general validity and disinterestedness of drug trials, given that academics are increasingly promoted for pursuing company agendas. As the Canadian MRC did not take up funding of her work when the company withdrew, she wonders who has an incentive to pursue findings that drugs lack efficacy.
David Weatherall, of Oxford University's Institute of Molecular Medicine, spoke about the spiralling costs of research and how this makes company involvement inevitable. But he is concerned by the way an increased reliance on industrial sponsors leads to conflicts of interest, bias, contractual pressures and even ghost writing of papers for industrial colleagues. He called for changes to reduce the pressure for short-term gain, rationalization of patent law for biologicals, funding to give scientists long-term careers in clinical science, protection for scientists and, should any dispute arise, external, disinterested review.
There was widespread concern at the meeting that current measures to handle potential conflicts of interest were inadequate. While some funding agencies, universities and journals require information about commercial interests, many believe a much larger-scale process is needed. "Science is international and measures are needed to reflect this," says Evans. But there was also concern not to develop a 'policing and punishing' regime. Many believe that an approach that educates researchers about the issues could lead to a situation where someone in every laboratory knows what should and should not be done in pursuit of these concerns, she says.
A new innovation in the US to help tackle these issues is a website listing researchers and their funding interests. The website reveals the
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With the human genome project exciting commercial interests, many researchers face growing pressure to seek industrial funding but there are mounting concerns about how their academic credentials can be protected, writes Nigel Williams.
names of more than 1,100 university researchers and dozens of non-profit organizations whose work is being underwritten by the private sector. The disclosure follows reports that scientists have been pressured to tailor research for the sake of sponsoring corporations and that journal editors have not disclosed potential conflicts.
The site was launched by the non-profit Center for Science in the Public Interest based in Washington DC. Director Michael Jacobsen said: "Corporations increasingly are funding academic scientists to conduct research… and provide advice. Too frequently, neither the scientists or the corporations disclose that."
Concern about such conflicts of interest has escalated in the past two years. The New England Journal of Medicine admitted that it had published at least 19 articles by authors who had financial connections to drug companies involved with the subject of their work. Despite this, a study released last month found that of 61,000 articles in 181 journals, just 0.5% disclosed potential conflicts.
Sheldon Krimsky, a professor of environmental policy at Tufts University, who studies such conflicts, said that because there was no law requiring the disclosure of financial conflicts of interest among scientists, the site 'provides a valuable way for citizens and the media to gain a better understanding of an important source of bias.'
Organizers of the site said they wanted potential conflicts disclosed, particularly by journalists who used academics as sources. Ronald Collins, director of the project said: "All too often reporters quoted scientists without providing the public with information about their ties to industry." "What people want is openness and a situation where researchers can freely express their doubts," says Evans.
